Apitegromab Slows Lean Mass Loss in Obesity Trial but Lacks Functional Gains
In a phase 2 trial, adding apitegromab to tirzepatide reduced lean mass loss during weight reduction but failed to improve ...
In a phase 2 trial, adding apitegromab to tirzepatide reduced lean mass loss during weight reduction but failed to improve ...
In a murine model of hypertrophic cardiomyopathy, four weeks of activin receptor inhibition with CDD866 increased skeletal muscle mass, attenuated ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.